GC Genome Corp (340450)

Overview

GC Genome Corp is a South Korean biotechnology company that focuses on clinical genome analysis and advanced genetic testing services. Established in 2013 and headquartered in Yongin, South Korea, the company addresses a diverse range of healthcare needs by offering over 300 genetic tests. Key areas of expertise include prenatal and newborn screening, health assessments for healthy individuals, precision diagnostics for cancer, and the identification of rare genetic diseases. Utilizing advanced technologies such as next-generation sequencing (NGS) and artificial intelligence, GC Genome delivers solutions aimed at disease detection, risk assessment, and facilitating personalized medicine. Recognized for its proprietary platforms, including Genome Health—a single nucleotide polymorphism (SNP) genotyping service for evaluating multi-disease risks—GC Genome also specializes in AI-enhanced liquid biopsy tests for comprehensive cancer screening. The company actively engages in international collaborations and invests significantly in research and development to innovate diagnostic methods, contributing to both national and global research efforts. As a key member of the GC Biopharma group, GC Genome is integral to South Korea's precision medicine ecosystem, striving to enhance human health through early detection, customized treatments, and genomic insights.

Products and Services

• Prenatal Screening: This service offers expectant parents crucial information about potential genetic disorders in their developing fetus, allowing for early detection and informed decision-making.
• Newborn Screening: GC Genome provides essential tests shortly after birth to identify rare genetic and metabolic disorders, ensuring timely intervention and better health outcomes for newborns.
• Health Checkups for Healthy Individuals: A comprehensive set of genetic assessments aimed at evaluating inherited risks and genetic predispositions in otherwise healthy individuals, empowering them to make proactive health decisions.
• Cancer Precision Diagnostics: Utilizing cutting-edge technologies, this service offers tailored cancer diagnostics that help in identifying specific cancer types and informing personalized treatment strategies.
• Diagnosis of Rare Genetic Diseases: GC Genome specializes in identifying rare genetic conditions through advanced genomic testing, connecting patients and families to vital information and support resources.
• Genome Health Platform: A proprietary SNP genotyping service that assesses multiple diseases, providing insight into individual genetic risks and aiding in preventative health strategies.
• AI-driven Liquid Biopsy Tests: This innovative screening method utilizes advanced AI algorithms to analyze genetic material in blood, facilitating non-invasive testing for early cancer detection.